Monkeypox cases in the US have drastically decreased, CDC data shows (OTCMKTS:BVNRY)


Monkeypox new disease dangerous over the world. Patient with Monkey Pox. Painful rash, red spots blisters on the hand. Close up rash, human hands with Health problem. Banner, copy space.

Marina Demidiuk

Cases of monkeypox in the US have been on a steady decline since peaking in August, CDC data shows.

As of Oct. 26, the 7-day moving average of daily cases was 30. That’s down from a 7-day moving average peak of 446 on August 7.

As of Oct. 26, HHS’ Administration for Strategic Preparedness and Response (OTC:ASPR) has shipped ~851.3K vials of Bavarian Nordic’s (OTCPK:BVNKF)(OTCPK:BVNRY) Jynneos vaccine to states. The CDC reports just over 1M doses have been administered (The discrepancy is because the shot has been given intradermally since August, using one-fifth of the amount that would be used if given subcutaneously, to stretch out supply.).

ASPR has previously stated it will make 1.1M vials available.

After hitting a 52-week high of $58.02 on Aug. 4, Bavarian Nordic (OTCPK:BVNRY) shares are down 48% since then.

SIGA Technologies, the maker of TPOXX, a smallpox therapy that can be used to treat monkeypox, is also down ~66% since its 52-week high of $26.96 on Aug 15.

Read Seeking Alpha contributor Clinically Sound Investor’s argument for why SIGA (SIGA) and monkeypox have both peaked.



Source link

Ozinize
Logo
Shopping cart